About admin

This author has not yet filled in any details.
So far admin has created 39 blog entries.

보로노이, 美오릭에 폐암 치료제 7200억 기술수출

2020-10-22T18:49:45+00:00

EGFR/HER2 Exon20 ins. 돌연변이 폐암 및 고형암 치료 뇌 전이암까지도 치료 가능한 정밀 표적신약 美 나스닥 상장사 ORIC에 7200억원 기술이전

보로노이, 美오릭에 폐암 치료제 7200억 기술수출2020-10-22T18:49:45+00:00

Sangjin Lee

2020-01-13T19:37:00+00:00

Bank of Korea Seoul National University, Economics, B.A. Sangjin Lee / Human Resources we strive to set up a proper KPI and continuously improve the foundation for fair evaluation of the passions and efforts of all colleagues in respective positions, which eventually leads to Voronoi’s culture. "Prior to joining Voronoi, I have served for the Bank of Korea over 10 years in various areas including business management, foreign exchange reserves management strategy, performance evaluation system, and macroeconomic analysis and forecast. During the time at the Bank of Korea, it was a meaningful experience to work with global investment banks in New York, USA, as I had a chance to look at how the performance-oriented and open organizational culture, which is different from the seniority-based Korean corporate organization, actually works. At Voronoi, I am responsible for establishing KPIs and organization operation. Voronoi is a young company with diverse range of professionals with outstanding careers ranging from business development, IPR, legal, strategy, patents, management support, AI, and clinical development, as well as key science areas related to new drug development such as new drugs synthesis and biotechnology. The value spectrum of each and every individual is as diverse as our specializations towards growth. With this in mind, we strive to set up a proper KPI and continuously improve the foundation for fair evaluation of the passions and efforts of all colleagues in respective positions, which eventually leads to Voronoi’s culture. " Bank of Korea Seoul National University, Economics, B.A. Sangjin Lee / Human Resources we strive to set up a proper KPI and continuously improve the foundation for fair evaluation of the passions and efforts of all colleagues in respective positions, which eventually leads to Voronoi’s culture. "Prior to joining Voronoi, I have served for the Bank of Korea over 10 years in various areas including business management, foreign exchange reserves management strategy, performance evaluation system, and macroeconomic analysis and forecast. During the time at the Bank of Korea, it was a meaningful experience to work with global investment banks in New York, USA, as I had a chance to look at how the performance-oriented and open organizational culture, which is different from the seniority-based Korean corporate organization, actually works. At Voronoi, I am responsible for establishing KPIs and organization operation. Voronoi is a young company with diverse range of professionals with outstanding careers ranging from business development, IPR, legal, strategy, patents, management support, AI, and clinical development, as well as key science areas related to new drug development such as new drugs synthesis and biotechnology. The value spectrum of each and every individual is as diverse as our specializations towards growth. With this in mind, we strive to set up a proper KPI and continuously improve the foundation for fair evaluation of the passions and efforts of all colleagues in respective positions, which eventually leads to Voronoi’s culture. "

Sangjin Lee2020-01-13T19:37:00+00:00

Young Mo Kang, MD, PhD

2020-01-14T15:50:49+00:00

Young Mo Kang, MD, PhD Department of Internal Medicine, Kyungpook National University School of Medicine, Korea Dr. Kang is currently professor in Kyungpook National School of Medicine, Department of Internal Medicine and Biochemistry & Cell Biology. Dr. Kang has special expertise in Rheumatology area. Dr. Kang’s educational background goes back to 1986, when he achieved his B.S. degree in Medicine in Kyungpook National University. He then achieved his PhD degree in the same school in year 1996. He then joined as an instructor in department of internal medicine in Dongguk University School of Medicine. He then became professor in Kyungpook National University, Department of Internal Medicine in 1997 and since then he is still serving his role as a professor in the same school. In 1991, he served his post-doctoral fellowship in Mayo Clinic in USA where he focused the research of Rheumatology in Department of Medicine and Immunology. Dr. Kang also served as a chairman of Department of Internal Medicine from 2014 to 2016. Dr. Kang is currently CEO of Preclina Inc. as well. Dr. Kang is currently a member of American Association of Immunologists, American Society of Matrix Biology, Asian Pacific League of Rheumatologists, Korean College of Rheumatology and an International Fellow Member of American College of Rheumatology. He has also been a steering committee of The Korean Study Group of Synovitis Research since 2007 and editor-in-chief of World Journal of Rheumatology since 2015. Dr. Kang was a principal investigator of clinical trials of Tofacitinib (Pfizer) and Filgotinib (Galapagos). Young Mo Kang, MD, PhD Department of Internal Medicine, Kyungpook National University School of Medicine, Korea Dr. Kang is currently professor in Kyungpook National School of Medicine, Department of Internal Medicine and Biochemistry & Cell Biology. Dr. Kang has special expertise in Rheumatology area. Dr. Kang’s educational background goes back to 1986, when he achieved his B.S. degree in Medicine in Kyungpook National University. He then achieved his PhD degree in the same school in year 1996. He then joined as an instructor in department of internal medicine in Dongguk University School of Medicine. He then became professor in Kyungpook National University, Department of Internal Medicine in 1997 and since then he is still serving his role as a professor in the same school. In 1991, he served his post-doctoral fellowship in Mayo Clinic in USA where he focused the research of Rheumatology in Department of Medicine and Immunology. Dr. Kang also served as a chairman of Department of Internal Medicine from 2014 to 2016. Dr. Kang is currently CEO of Preclina Inc. as well. Dr. Kang is currently a member of American Association of Immunologists, American Society of Matrix Biology, Asian Pacific League of Rheumatologists, Korean College of Rheumatology and an International Fellow Member of American College of Rheumatology. He has also been a steering committee of The Korean Study Group of Synovitis Research since 2007 and editor-in-chief of World Journal of Rheumatology since 2015.

Young Mo Kang, MD, PhD2020-01-14T15:50:49+00:00

Jae Hee Cheon

2020-01-31T11:32:04+00:00

Jae Hee Cheon, MD, PhD Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea Dr. Cheon is currently MD in Yonsei University and he focuses in gastroenterology field. He graduated Seoul National University of Medicine in 1996 and obtained his PhD degree in 2006 at the same school. He conducted his post-graduate training in Seoul National University Hospital from 1996 to 2005. Dr. Cheon’s focus area is internal medicine and especially gastroenterology. More specifically, he has expertise in inflammatory bowel disease such as Crohn disease, Ulcerative colitis, and Behcet’s disease. Dr. Cheon received board certification in internal medicine in 2001, gastrointestinal endoscopy in 2006, gastroenterology and hepatology in 2007. He is also a current member of Institutional Review Board of Severance Hospital since 2007, Research Committee of Yonsei University since 2014, The Korean society of Gastroenterology, Hepatology, Gastrointestinal Endoscopy, etc. Dr. Cheon has received more than 20 honors and awards including the best research award in Korean FDA research and development exhibition in 2018. and best professor for referral treatment in 2014. Dr. Cheon was a principal investigator of Humira of Abbvie and Keytruda of Merck. Dr. Cheon has published more than 280+ publications over areas in intestinal disease, inflammatory bowel disease, colorectal neoplasms, etc. Jae Hee Cheon, MD, PhD Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea Dr. Cheon is currently MD in Yonsei University and he focuses in gastroenterology field. He graduated Seoul National University of Medicine in 1996 and obtained his PhD degree in 2006 at the same school. He conducted his post-graduate training in Seoul National University Hospital from 1996 to 2005. Dr. Cheon’s focus area is internal medicine and especially gastroenterology. More specifically, he has expertise in inflammatory bowel disease such as Crohn disease, Ulcerative colitis, and Behcet’s disease. Dr. Cheon received board certification in internal medicine in 2001, gastrointestinal endoscopy in 2006, gastroenterology and hepatology in 2007. He is also a current member of Institutional Review Board of Severance Hospital since 2007, Research Committee of Yonsei University since 2014, The Korean society of Gastroenterology, Hepatology, Gastrointestinal Endoscopy, etc. Dr. Cheon has received more than 20 honors and awards including the best research award in Korean FDA research and development exhibition in 2018. and best professor for referral treatment in 2014. Dr. Cheon was a principal investigator of Humira of Abbvie and Keytruda of Merck. Dr. Cheon has published more than 280+ publications over areas in intestinal disease, inflammatory bowel disease, colorectal neoplasms, etc.

Jae Hee Cheon2020-01-31T11:32:04+00:00

(Korean) 다나파버암센터, 보로노이 방문…”공동연구 강화 등 파트너십 공고화”

2019-12-30T18:57:07+00:00

Sorry, this entry is only available in Korean.

(Korean) 다나파버암센터, 보로노이 방문…”공동연구 강화 등 파트너십 공고화”2019-12-30T18:57:07+00:00

(Korean) 2019 보로노이 심포지엄 성료…국내외 의학계 별들 모였다 – 한국경제

2019-12-30T18:35:36+00:00

Sorry, this entry is only available in Korean.

(Korean) 2019 보로노이 심포지엄 성료…국내외 의학계 별들 모였다 – 한국경제2019-12-30T18:35:36+00:00

Dana-Farber Cancer Institute grants exclusive right of protein degradation patent to Voronoi – Asia Biz

2019-12-30T18:22:31+00:00

Dana-Farber Cancer Institute grants exclusive right of protein degradation patent to Voronoi-AsiaBiz View the update

Dana-Farber Cancer Institute grants exclusive right of protein degradation patent to Voronoi – Asia Biz2019-12-30T18:22:31+00:00